COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL

被引：0
|
作者：
Sasse, Andre [1 ]
Carvalho, Adriana [1 ]
机构：
[1] Univ Estadual Campinas, UNICAMP, Ctr Evidence Oncol, CEVON, Campinas, SP, Brazil
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 194 - 198
  • [42] THE COST EFFECTIVENESS ANALYSIS OF CAPDX VERSUS FOLFOX-4 REGIMENS WITH OR WITHOUT BEVACIZUMAB IN THE FIRST LINE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN HONG KONG
    Lee, V. W.
    Cheng, F.
    Wan, K. P.
    Chik, J.
    Chan, D.
    Cheng, A.
    Wong, K. H.
    VALUE IN HEALTH, 2017, 20 (05) : A109 - A109
  • [43] First-line cetuximab gives longer survival than bevacizumab in metastatic colorectal cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (07) : 370 - 370
  • [44] COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL
    Caponero, R.
    Saggia, M. G.
    Nasciben, V. D.
    Santos, E. A.
    Stefani, S.
    VALUE IN HEALTH, 2008, 11 (06) : A474 - A475
  • [45] A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
    Graham, Christopher N.
    Christodoulopoulou, Alexandra
    Knox, Hediyyih N.
    Sabatelli, Lorenzo
    Hechmati, Guy
    Garawin, Tamer
    Strickler, John H.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (11) : 1075 - 1083
  • [46] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [47] Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making
    Franken, Mira D.
    Koopman, Miriam
    van Oijen, Martijn G. H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (02): : 214 - 214
  • [48] Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6
    Perrocheau, G.
    Bennouna, J.
    Ducreux, M.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Dominguez, S.
    Faroux, R.
    Florentin, V.
    Douillard, J. Y.
    ONCOLOGY, 2010, 79 (3-4) : 174 - 180
  • [49] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [50] ASPECCT: panitumumab versus cetuximab for colorectal cancer
    Sunakawa, Yu
    Ichikawa, Wataru
    Sasaki, Yasutsuna
    LANCET ONCOLOGY, 2014, 15 (08): : E301 - E302
12345